Langer-Giedion syndrome, also known as Trichorhinophalangeal Syndrome Type II, is a genetic condition that causes bone abnormalities and distinctive facial features. The cause of Langer Giedion syndrome is having multiple benign bone tumors called extoses which results in limited range of joint movement, and pressure on the nerves, blood vessels, the spinal cord, and the tissues surrounding the extoses. Appearance wise affected individuals have short stature, sparse scalp hair, a rounded nose, a long flat area between the nose and the upper lip, and a thin upper lip. People with Langer Giedion syndrome may also have some intellectual disabilities. Langer Giedion syndrome is extremely rare and has no cure or treatment.
Langer-giedion Syndrome Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Langer-giedion Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 958 products for the study of Langer-giedion Syndrome that can be applied to Western Blot, Chromatin Immunoprecipitation, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.
Langer-giedion Syndrome is also known as Giedion-langer Syndrome, Langer Giedion Syndrome, Syndrome, Langer-giedion, Trichorhinophalangeal Syndrome Type Ii, Trichorhinophalangeal Syndrome With Exostoses.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.